Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Michael Wonder & Geoffrey Chin. (2015) What impact does ‘conventional’ economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005–2012). Expert Review of Pharmacoeconomics & Outcomes Research 15:5, pages 843-850.
Read now
Read now
Articles from other publishers (12)
Victoria Charlton. (2022) Does NICE apply the rule of rescue in its approach to highly specialised technologies?. Journal of Medical Ethics 48:2, pages 118-125.
Crossref
Crossref
Néboa Zozaya, Teresa Caballero, Teresa González-Quevedo, Pedro Gamboa Setien, M. Ángeles González, Ramón Jódar, José Luis Poveda-Andrés, Encarna Guillén-Navarro, Agustín Rivero Cuadrado & Álvaro Hidalgo-Vega. (2022) A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain. Global & Regional Health Technology Assessment 9, pages 14-21.
Crossref
Crossref
Tamás Zelei, Nicholas D. Mendola, Baher Elezbawy, Bertalan Németh & Jonathan D. Campbell. (2021) Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review. PharmacoEconomics - Open 5:4, pages 605-612.
Crossref
Crossref
Alessandra Blonda, Yvonne Denier, Isabelle Huys & Steven Simoens. (2021) How to Value Orphan Drugs? A Review of European Value Assessment Frameworks. Frontiers in Pharmacology 12.
Crossref
Crossref
Carina Schey, Maarten Jacobus Postma, Paul F. M. Krabbe, Olekdandr Topachevskyi, Andrew Volovyk & Mark Connolly. (2020) Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases. Frontiers in Public Health 8.
Crossref
Crossref
Marcin Czech, Aleksandra Baran-Kooiker, Kagan Atikeler, Maria Demirtshyan, Kamilla Gaitova, Malwina Holownia-Voloskova, Adina Turcu-Stiolica, Coen Kooiker, Oresta Piniazhko, Natella Konstandyan, Olha Zalis'ka & Jolanta Sykut-Cegielska. (2020) A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries. Frontiers in Public Health 7.
Crossref
Crossref
Mónica D. Oliveira, Inês Mataloto & Panos Kanavos. (2019) Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. The European Journal of Health Economics 20:6, pages 891-918.
Crossref
Crossref
Eric Faulkner, Daryl S. Spinner, Moira Ringo & Marissa Carroll. (2019) Are Global Health Systems Ready for Transformative Therapies?. Value in Health 22:6, pages 627-641.
Crossref
Crossref
Daria Korchagina, Szymon Jaroslawski, Guy Jadot & Mondher Toumi. 2019. Regulatory and Economic Aspects in Oncology. Regulatory and Economic Aspects in Oncology
109
142
.
Aleksandra Baran-Kooiker, Marcin Czech & Coen Kooiker. (2018) Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development?. Frontiers in Public Health 6.
Crossref
Crossref
Katarzyna Kolasa, Krzysztof M. Zwolinski, Zoltan Kalo & Tomasz Hermanowski. (2016) Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs. Orphanet Journal of Rare Diseases 11:1.
Crossref
Crossref
Sojung Hwang, 배은영 & 이태진. (2015) 의약품 급여 결정과 다기준의사결정(Multiple Criteria Decision Analysis) 활용에 대한 고찰. The Journal of Health Technology Assessment 3:2, pages 75-89.
Crossref
Crossref